SCHEMBL6012034

SCHEMBL6012034

O=C(CN1CCOCC1)N1CCC(/C=C\c2ccc(Cl)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
GFER P55789 1/20 0.46
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
FKBP1A P62942 1/20 0.43
NAMPT P43490 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KMT2A Q03164 2/20 0.41
MAOA P21397 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2718666 1.00 MAOB (0.50) MAOBNPC1RAB9AL3MBTL1ALOX15
SCHEMBL2718661 1.00 MAOB (0.50) MAOBNPC1RAB9AL3MBTL1ALOX15
SCHEMBL6011040 0.96 MAOB (0.46) MAOBNPC1RAB9AL3MBTL1ALOX15
SCHEMBL6011036 0.91 ALOX15 (0.50) MAOBNPC1ALOX15TSHRHSD17B10
SCHEMBL6011051 0.88 ALOX15 (0.48) MAOBNPC1ALOX15TSHRHSD17B10
SCHEMBL6011748 0.88 MAOB (0.50) MAOBNPC1ALOX15TSHRHSD17B10
SCHEMBL6011774 0.88 ALDH1A1 (0.53) MAOBNPC1RAB9AALOX15TSHR
SCHEMBL14261815 0.88 MAOB (0.50) MAOBL3MBTL1ALOX15TSHRHSD17B10
SCHEMBL6012010 0.88 TSHR (0.48) MAOBNPC1L3MBTL1ALOX15TSHR
SCHEMBL14261828 0.88 MAOB (0.50) MAOBNPC1ALOX15TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D MAOB 3198/4885NPC1 762/4885RAB9A 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.